The effect of EEG biofeedback on reducing postcancer cognitive impairment

Integrative Cancer Therapies

Volumn 12, Issue 6, 2013, Pages 475-487

  Alvarez, Jean ^a   Meyer, Fremonta L ^b,e   Granoff, David L ^c   Lundy, Allan ^d  

^a Applied Brain Research Foundation of Ohio   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c Lake Erie Brain Performance Institute   (United States)

^d Independent Research Consultant   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

brain computer interface; cancer; chemobrain; chemofog; cognitive impairment; EEG biofeedback; fatigue; neurofeedback; oncology; survivorship

Indexed keywords

ADULT; ANXIETY DISORDER; BREAST CANCER; BRIEF SYMPTOM INVENTORY; CANCER CHEMOTHERAPY; CANCER SURVIVOR; CLINICAL ARTICLE; CLINICAL ASSESSMENT TOOL; COGNITIVE DEFECT; DEPRESSION; DISEASE SEVERITY; FATIGUE; FEMALE; FOLLOW UP; FUNCTIONAL ASSESSMENT OF CANCER THERAPY COGNITIVE FUNCTION; FUNCTIONAL ASSESSMENT OF CHRONIC ILLNESS THERAPY FATIGUE; HUMAN; LATENT PERIOD; NEUROFEEDBACK; OUTCOME ASSESSMENT; PITTSBURGH SLEEP QUALITY INDEX; POSTCANCER COGNITIVE IMPAIRMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSYCHOLOGICAL RATING SCALE; QUALITY OF LIFE; REVIEW; SELF REPORT; SLEEP DISORDER; SLEEP PATTERN; SLEEP QUALITY; SOMATIZATION;

BRAIN-COMPUTER INTERFACE; CANCER; CHEMOBRAIN; CHEMOFOG; COGNITIVE IMPAIRMENT; EEG BIOFEEDBACK; FATIGUE; NEUROFEEDBACK; ONCOLOGY; SURVIVORSHIP;

ADULT; AGED; ANALYSIS OF VARIANCE; ANTINEOPLASTIC AGENTS; ANXIETY; BREAST NEOPLASMS; COGNITION DISORDERS; DEPRESSION; FATIGUE; FEASIBILITY STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; NEUROFEEDBACK; PROSPECTIVE STUDIES; PSYCHIATRIC STATUS RATING SCALES; QUALITY OF LIFE; SLEEP DISORDERS; SURVIVORS; TIME FACTORS;

EID: 84886077807     PISSN: 15347354     EISSN: 1552695X     Source Type: Journal    
DOI: 10.1177/1534735413477192     Document Type: Review

References (45)

1. International Cognition and Cancer Task Force. Nature of the cognitive difficulties. http://www.icctf.com/index.php?16. Accessed December 18, 2012.
2. Meyers CA, Perry JR Cognition and Cancer. Meyers CA Perry JR, ed. New York, NY: Cambridge University Press ; 2008: 3-5.
3. Ahles TA, Saykin AJ, Furstenburg CT, et al. Neuropsychologic impact of standard-dose adjuvant chemotherapy in long-term survivors of breast cancer and lymphoma. J Clin Oncol. 2002 ; 20: 485-493
4. Ferguson RJ, Ahles TA. Low neuropsychologic performance among adult cancer survivors treated with chemotherapy. Curr Neurol Neurosci Rep. 2003 ; 3: 215-222
5. Wefel JS, Lenzi R, Theriault RL, Davis RN, Meyers CA. The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma: results of a prospective, randomized, longitudinal trial. Cancer. 2004 ; 100: 2292-2299
6. Deprez S, Amant F, Smeets A, et al. Longitudinal assessment of chemotherapy-induced structural changes in cerebral white matter and its correlation with impaired cognitive functioning. J Clin Oncol. 2012 ; 30: 274-281
7. Koppelmans V, Breteler MMB, Boogerd W, Seynaeve C, Gundy C, Schagen SB. Neuropsychological performance in survivors of breast cancer more than 20 years after adjuvant chemotherapy. J Clin Oncol. 2012 ; 30: 1080-1086
8. Ferguson RJ, McDonald BC, Saykin AJ, Ahles TA. Brain structure and function differences in monozygotic twins: possible effects of breast cancer chemotherapy. J Clin Oncol. 2007 ; 25: 3866-3870
9. Vardy J, Wong K, Yi Q, et al. Assessing cognitive function in cancer patients. Support Care Cancer. 2006 ; 14: 1111-1118
10. Ganz PA, Desmond KA, Leedham B, Rowland JH, Meyerowitz BE, Belin TR. Quality of life in long-term, disease-free survivors of breast cancer: a follow-up study. J Natl Cancer Inst. 2002 ; 94: 39-48
11. Saykin AJ, Ahles TA, Schoenfeld JD. Grey matter reduction on voxel-based morphometry in chemotherapy-treated cancer survivors. J Int Neuropsychol Soc. 2003 ; 9: 246
12. Stemmer S, Stears J, Burton BS, Jones RB, Simon JH. White matter changes in patients with breast cancer treated with high-dose chemotherapy and autologous bone marrow support. Am J Neuroradiol. 1994 ; 15: 1267-1273
13. Janelsins ML, Roscoe JA, Berg MJ, et al. IGF-1 partially restores chemotherapy-induced reductions in neural cell proliferation in adult C57BL/6 mice. Cancer Invest. 2010 ; 28: 544-553
14. Myers JS. The possible role of cytokines in chemotherapy-induced cognitive deficits. Adv Exp Med Biol. 2010 ; 678: 119-123
15. Lower E, Fleishman S, Cooper A, et al. A phase III, randomized placebo-controlled trial of the safety and efficacy of d-MPH as new treatment of fatigue and "chemobrain" in adult cancer patients. J Clin Oncol. 2005 ; 239: 729s
16. Kohli S, Fisher SG, Tra Y, Wesnes K, Morrow GR. The cognitive effects of modafinil in breast cancer survivors: a randomized clinical trial. J Clin Oncol. 2007 ; 25: 9004
17. Ferguson RJ, Ahles TA, Saykin A.J, et al. Cognitive-behavioral management of chemotherapy-related cognitive change. Psychooncology. 2007 ; 16: 772-777
18. Ferguson RJ, McDonald BC, Rocque MA, et al. Development of CBT for chemotherapy-related cognitive change: results of a waitlist control trial. Psychooncology. 2012 ; 21: 176-186
19. Kim SJ, Stasio C, Spina LM, Tinker DE, Kluse M, Mahnke HW. Improved cognitive function and quality of life in individuals with " chemobrain" after using a brain-plasticity-based training program. Poster presented at: the 32nd Annual Symposium of the American Society of Breast Disease ; San Diego, CA ;..
20. Merzenich MM, Tallal P, Peterson B, Miller S, Jenkins WM Neuronal Plasticity: Building a Bridge From the Laboratory to the Clinic. Grafman J Christen Y, ed. Berlin, Germany: Springer-Verlag ; 1999: 169-187.
21. Mahncke HW, Connor BB, Appelman J, et al. Memory enhancement in healthy older adults using a brain plasticity-based training program: a randomized, controlled study. Proc Natl Acad Sci U S A. 2006 ; 103: 12523-12528
22. MooreHCFParsonsMWYueGHRybickiLASiemionowV. EEG for evaluation of "chemobrain."Poster presented at: 2012 meeting of the American Society of Clinical Oncology; June 1-5, 2012; Chicago, IL. http://www.asco.org/ASCOv2/ Meetings/Abstracts?&vmview=abst-detail-view&confID=114&abstractID= 95352. Accessed December 18, 2012.
23. Doidge N. The brain that changes itself: the neuroplasticity revolution and film clips of people undergoing plastic change. Keynote address at: 18th Annual Conference of the International Society for Neurofeedback and Research ; Denver, CO ;..
24. Ros T, Munneke MA, Ruge D, Gruzelier JH, Rothwell JC. Endogenous control of waking brain rhythms induces neuroplasticity in humans. Eur J Neurosci. 2010 ; 31: 770-778
25. Ros T, Theberge J, Frewen PA, et al. Mind over chatter: plastic upregulation of the fMRI salience network directly after EEG neurofeedback. Neuroimage. 2013 ; 65: 324-335
26. Duffy FH. The state of EEG biofeedback therapy (EEG operant conditioning) in 2000: an editor's opinion. Clin EEG Neurosci. 2000 ; 31: v
27. EEGInfo. Neurofeedback research: head injury. http://www.eeginfo.com/ research/headinjury-main.html. Accessed December 18, 2012.
28. McDonald BC, Saykin AJ, Ahles TA Cognition and Cancer. Meyers CA Perry JR, ed. New York, NY: Cambridge University Press ; 2008: 19-32.
29. Demos JN Getting Started With Neurofeedback. New York, NY: Norton ; 2005 :
30. Kelso JAS Dynamic Patterns: The Self-organization of Brain and Behavior (Complex Adaptive Systems). Boston, MA: Massachusetts Institute of Technology Press ; 1995 :
31. Freeman WJ Modeling Phase Transitions in the Brain. Steyn-Ross DA Steyn-Ross M, ed. New York, NY: Springer ; 2010 :
32. Steyn-Ross DA, Steyn-Ross M Modeling Phase Transitions in the Brain (Springer Series in Computational Neuroscience). New York, NY: Springer ; 2010 :
33. Wefel JS. An overview of the clinical and research aspects of cognition and cancer. Paper presented at: Annual meeting of the International Cognition and Cancer Task Force ; New York, NY ;..
34. Ganz PA, Desmond KA, Leedham B, Rowland JH, Meyerowitz BE, Belin TR. Quality of life in long-term, disease-free survivors of breast cancer: a follow-up study. J Natl Cancer Inst. 2002 ; 94: 39-48
35. Vardy J, Wong K, Yi Q, et al. Assessing cognitive function in cancer patients. Support Care Cancer. 2006 ; 14: 1111-1118
36. Wagner L, Sweet JJ, Butt Z, Lai J, Cella D. Measuring patient self-reported cognitive function: qualitative findings and initial development of the functional assessment of cancer therapy - cognitive function (FACT-COG) instrument. J Support Oncol. 2009 ; 7: W32 - W39
37. Bower JE. Behavioral symptoms in patients with breast cancer and survivors. J Clin Oncol. 2008 ; 26: 768-777
38. Brezden CB, Phillips K-A, Abdolell M, Bunston T, Tannock IF. Cognitive function in breast cancer patients receiving adjuvant chemotherapy. J Clin Oncol. 2000 ; 18: 2695-2701
39. Meyers CA, Albitar M, Estey E. Cognitive impairment, fatigue, and cytokine levels in patients with acute myelogenous leukemia or myelodysplastic syndrome. Cancer. 2005 ; 104: 788-793
40. Asher A. Cognitive dysfunction among cancer survivors. Am J Phys Med Rehabil. 2011 ; 90: S16 - S26
41. Cella D Manual of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System. Evanston, IL: Centre on Outcomes, Research and Education (CORE), Evanston Northwestern Healthcare and Northwestern University ; 1997 :
42. Buysse DJ, Reynolds CF, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index (PSQI): a new instrument for psychiatric research and practice. Psychiatry Res. 1989 ; 28: 193-213
43. Derogatis LR Brief Symptom Inventory (BSI)-18. Administration, Scoring and Procedures Manual. Minneapolis, MN: NCS Pearson ; 2001 :
44. Wagner LI.. Paper presented at: Annual meeting of the International Cognition and Cancer Task Force ; Amsterdam, Netherlands ;..
45. Cella DF, Zagari MJ, Vandoros C, et al. Epoetin alfa treatment results in clinically significant improvements in quality of life in anemic cancer patients when referenced to the general population. J Clin Oncol. 2003 ; 21: 366-373